Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients

被引：0
作者：
Agarwal, Kosh [1 ]
Castells, Lluis [2 ]
Mullhaupt, Beat [3 ]
Rosenberg, William M. [4 ]
McNabb, Brian L. [5 ]
Arterburn, Sarah [6 ]
Camus, Gregory [7 ]
McNally, John [5 ]
Brainard, Diana M. [5 ]
Subramanian, Mani [5 ]
Gonsalkorala, Enoka [1 ]
Londono, Maria [8 ,9 ]
Dufour, Jean-Francois [10 ]
Forns, Xavier [8 ,9 ]
机构：
[1] Kings Coll Hosp NHS Trust Fdn, London, England
[2] Hosp Univ Val dHebron, Barcelona, Spain
[3] Univ Hosp Zurich, Zurich, Switzerland
[4] UCL, Inst Liver & Digest Hlth, London, England
[5] Gilead Sci Inc, Clin Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[6] Gilead Sci Inc, Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA
[7] Gilead Sci Inc, Virol, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] Hosp Clin Barcelona, CIBEREHD, Barcelona, Spain
[9] IDIBAPS, Barcelona, Spain
[10] Univ Bern, Bern, Switzerland
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1069
引用
收藏
页码：571A / 571A
页数：1
相关论文
共 50 条
  • [21] Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
    Feld, J. J.
    Jacobson, I. M.
    Hezode, C.
    Asselah, T.
    Ruane, P. J.
    Gruener, N.
    Abergel, A.
    Mangia, A.
    Lai, C. -L.
    Chan, H. L. Y.
    Mazzotta, F.
    Moreno, C.
    Yoshida, E.
    Shafran, S. D.
    Towner, W. J.
    Tran, T. T.
    McNally, J.
    Osinusi, A.
    Svarovskaia, E.
    Zhu, Y.
    Brainard, D. M.
    McHutchison, J. G.
    Agarwal, K.
    Zeuzem, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) : 2599 - 2607
  • [22] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
    Foster, Graham R.
    Thompson, Alex J.
    Ruane, Peter J.
    Borgia, Sergio M.
    Dore, Gregory
    Workowski, Kimberly
    Hyland, Robert H.
    Wang, Jing
    Svarovskaia, Evguenia S.
    Stamm, Luisa M.
    Brainard, Diana M.
    Subramanian, Mani
    McHutchison, John G.
    Berg, Thomas
    Agarwal, Kosh
    Conway, Brian
    Feld, Jordan J.
    Willems, Bernard E.
    Roberts, Stuart K.
    HEPATOLOGY, 2016, 64 : 135A - 136A
  • [23] Meta-Analysis: Sustained Virologic Response at 12 Weeks (SVR12) With Simeprevir and Sofosbuvir (SMV plus SOF) in Liver Transplant (LT) Recipients With HCV Genotype 1 (HCV-1)
    Nghia Nguyen
    Yee, Brittany E.
    Lutchman, Glen
    Lim, Joseph K.
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2015, 148 (04) : S1091 - S1092
  • [24] Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial
    Wei, Lai
    Xie, Qing
    Huang, Yan
    Wu, Shanming
    Xu, Min
    Tang, Hong
    Cheng, Jun
    Gao, Yanhang
    Mou, Zhuangbo
    Dou, Xiaoguang
    Nan, Yuemin
    Ning, Qin
    Mao, Yimin
    Stamm, Luisa
    Lu, Sophia
    Dvory-Sobol, Hadas
    Mo, Hongmei
    Brainard, Diana
    Yang, Yongfeng
    Wang, Guiqiang
    Hu, Peng
    Zhang, Lunli
    Gao, Zhiliang
    Lin, Feng
    Shang, Jia
    Gong, Guozhong
    Li, Jun
    Su, Minghua
    Duan, Zhongping
    Hou, Jinlin
    Jia, Jidong
    HEPATOLOGY, 2018, 68 : 379A - 379A
  • [25] Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase
    Braeu, N.
    Wyles, D.
    Kottilil, S.
    Darr, E.
    Workowski, K.
    Luetkemeyer, A.
    Adeyemi, O.
    Ruane, P.
    Doehle, B.
    Huang, K. C.
    Osinusi, A.
    McNally, J.
    Natha, M.
    Guion, M.
    McLean, T.
    Brainard, D. M.
    McHutchison, J. G.
    Naggie, S.
    Sulkowski, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [26] Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index
    Benlloch, S
    Berenguer, M
    Prieto, M
    Rayón, JM
    Aguilera, V
    Berenguer, J
    LIVER TRANSPLANTATION, 2005, 11 (04) : 456 - 462
  • [27] A simple noninvasive index to predict fibrosis in HCV-infected liver transplant recipients
    Benlloch, S
    Berenguer, M
    Rayón, JM
    Prieto, M
    Aguilera, V
    Berenguer, J
    JOURNAL OF HEPATOLOGY, 2005, 42 : 45 - 45
  • [28] Alarming decrease in patient survival among HCV-infected liver transplant recipients
    Berenguer, M
    Prieto, M
    Aguilera, V
    Nicolas, D
    Carrasco, D
    Rayon, M
    Mir, J
    Berenguer, J
    JOURNAL OF HEPATOLOGY, 2001, 34 : 32 - 33
  • [29] SOFOSBUVIR PLUS VELPATASVIR FOR CHRONIC HCV GENOTYPE 1, 2, 3, AND 4 INFECTION
    Ahmed, H.
    Attia, A.
    Mohamed, A.
    Elgebaly, A.
    Negida, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S742 - S742
  • [30] DACLATASVIR PLUS SOFOSBUVIR FOR CHRONIC HCV-INFECTED KIDNEY TRANSPLANT RECIPIENTS - A PILOT STUDY OF EFFICACY AND SAFETY
    Duerr, M.
    Staeck, O.
    Khadzhynov, D.
    Schrezenmeier, E.
    Lehner, L.
    Budde, K.
    Halleck, F.
    TRANSPLANT INTERNATIONAL, 2016, 29 : 20 - 20
12345